Advertisement

Drugs & Aging

, Volume 35, Issue 4, pp 289–302 | Cite as

Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?

  • Hira S. Mian
  • Tanya M. Wildes
Review Article
  • 265 Downloads

Abstract

Multiple myeloma is a malignant plasma cell disease, which typically affects older patients, with a median age at diagnosis of 70 years. The recent introduction of novel drugs and ongoing improvements in supportive care have significantly contributed to overall better management and outcomes for patients with multiple myeloma. Autologous stem-cell transplantation has been a standard part of therapy for myeloma patients for many years, first in younger patients and increasingly in older, and may still be considered in selected older patients with myeloma. In addition, in both newly diagnosed patients and in the relapsed/refractory setting, a number of novel agents tested in large phase III trials have yielded improvements in overall outcomes. As clinical trials under-enrol older patients and have stringent exclusion criteria, the data and results from them may not be generalizable to all older adults. In this review, we examine the treatment options for older adults with myeloma with a specific focus on the currently available data on novel agents in this cohort. The clinical efficacy and unique toxicity profile of each novel agent must be considered prior to the treatment plan in older adults.

Notes

Compliance with Ethical Standards

Funding

No funding was required for this article.

Conflict of interest

H.M. has received speaker honoraria  from Janssen and Celgene and received financial support for an advisory board meeting for Amgen. T.W. serves as site PI on a study supported by Janssen.

References

  1. 1.
    Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 2008.Google Scholar
  2. 2.
    Altekruse SF KC, Krapcho M, Neyman N, Aminou R, Waldron W, et al. (eds). SEER Cancer Statistics Review, 1975–2007. Bethesda: National Cancer Institute. 2010.Google Scholar
  3. 3.
    Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.CrossRefPubMedGoogle Scholar
  4. 4.
    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–74.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910–21.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009;114(15):3139–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025–31.CrossRefPubMedGoogle Scholar
  11. 11.
    Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209–18.CrossRefPubMedGoogle Scholar
  12. 12.
    Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2009;113(15):3435–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Hulin C, Belch A, Shustik C, Petrucci MT, Duhrsen U, Lu J, et al. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol. 2016;34(30):3609–17.CrossRefPubMedGoogle Scholar
  14. 14.
    Pozzi S, Marcheselli L, Bari A, Liardo EV, Marcheselli R, Luminari S, et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol. 2013;163(1):40–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934–41.CrossRefPubMedGoogle Scholar
  16. 16.
    Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–17.CrossRefPubMedGoogle Scholar
  18. 18.
    Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127(21):2569–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259–66.CrossRefPubMedGoogle Scholar
  20. 20.
    Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337–41.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679–86.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus Bortezomib, Melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–28.CrossRefPubMedGoogle Scholar
  23. 23.
    Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–83.CrossRefPubMedGoogle Scholar
  24. 24.
    Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood. 1990;76(9):1860–6.PubMedGoogle Scholar
  26. 26.
    Gore ME, Selby PJ, Viner C, Clark PI, Meldrum M, Millar B, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet. 1989;2(8668):879–82.CrossRefPubMedGoogle Scholar
  27. 27.
    Fermand JP, Levy Y, Gerota J, Benbunan M, Cosset JM, Castaigne S, et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood. 1989;73(1):20–3.PubMedGoogle Scholar
  28. 28.
    Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298–301.PubMedGoogle Scholar
  29. 29.
    McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2(8354):822–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, et al. Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood. 2010;115(10):1873–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, et al. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol. 2014;25(1):189–95.CrossRefPubMedGoogle Scholar
  32. 32.
    Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, et al. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014;20(11):1796–803.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, et al. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016;101(11):1398–406.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    McCarthy PL Jr, Hahn T, Hassebroek A, Bredeson C, Gajewski J, Hale G, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995–2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transpl. 2013;19(7):1116–23.CrossRefGoogle Scholar
  36. 36.
    Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transpl. 2013;19(11):1615–24.CrossRefGoogle Scholar
  37. 37.
    Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transpl. 2015;50(2):209–15.CrossRefGoogle Scholar
  38. 38.
    Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345–50.CrossRefPubMedGoogle Scholar
  39. 39.
    Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124(4):536–45.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksac M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239–47.CrossRefPubMedGoogle Scholar
  43. 43.
    Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013;98(1):87–94.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015;33(33):3921–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301–10.  https://doi.org/10.1182/blood-2017-07-795047.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–27.CrossRefPubMedGoogle Scholar
  47. 47.
    O’Donnell EK, Laubach JP, Yee AJ, Huff CA, Basile FG, Wade PM, et al. A phase II study of modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2015;126(23):4217.Google Scholar
  48. 48.
    Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23(11):2147–52.CrossRefPubMedGoogle Scholar
  49. 49.
    Quach H, Harrison S, Fernyhough LJ, Henderson RA, Corbett G, Browett P, et al. Lower dose lenalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma who are aged 60 years or over and/or at risk of Myelosuppression: final analysis of the revlite trial and matched comparison to the MM009 and MM010 trials. Blood. 2015;126(23):4236.Google Scholar
  50. 50.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.CrossRefPubMedGoogle Scholar
  51. 51.
    Venner CP, Bahlis NJ, Neri PP, Sandhu I, Duggan P, Belch AR, Hewitt JD, Pilarski LM, Nikitina T, Jimenez-Zepeda V, et al. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the upfront therapy of transplant ineligible patients with multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2015;15:e260–e1.CrossRefGoogle Scholar
  52. 52.
    Tuchman SA, Moore JO, DeCastro CD, Li Z, Sellars E, Kang Y, et al. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. J Geriatr Oncol. 2017;8(3):165–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Jimenez Zepeda VH, Duggan P, Neri PE, Bahlis NJ. Cyclophosphamide, bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant eligible multiple myeloma patients. Blood. 2014;124(21):5751.Google Scholar
  54. 54.
    Yagi H, Fujiwara R, Sano K, Mariko F, Iizuka T, Yamazaki K, et al. Reduced-dosage of three drugs combination of cyclophosphamide, bortezomib and dexamethasone (reduced-CyBorD) retains high response rate with less toxicities in elderly patients with multiple myeloma. Blood. 2012;120(21):1865.Google Scholar
  55. 55.
    Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557–60.CrossRefPubMedGoogle Scholar
  56. 56.
    Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–40.CrossRefPubMedGoogle Scholar
  57. 57.
    San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–66.CrossRefGoogle Scholar
  58. 58.
    Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127(21):2561–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Cromm PM, Crews CM. The proteasome in modern drug discovery: second life of a highly valuable drug target. ACS Central Sci. 2017;3(8):830–8.CrossRefGoogle Scholar
  60. 60.
    Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.CrossRefPubMedGoogle Scholar
  61. 61.
    Weisel KC, Siegel D, San Miguel JF, Hájek R, Ho PJ, Gaidano G, Orlowski RZ, Zhou L, Kimball AS, Moreau P. Overall survival of patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone versus bortezomib and dexamethasone according to prior line of therapy and previous exposure to bortezomib: secondary analysis of the phase 3 endeavor study. Blood. 2017;130(Suppl 1):1850.Google Scholar
  62. 62.
    Niesvizky R, Ludwig H, Spencer A, Goldschmidt H, Pika T, Mateos M, Dimopoulos MA, Zhou L, Kimball AS, Facon T. Overall survival of relapsed/refractory multiple myeloma patients treated with carfilzomib and dexamethasone Vs bortezomib and dexamethasone: results from the phase 3 endeavor study according to age subgroup. Blood. 2017;130(Suppl 1):1885.Google Scholar
  63. 63.
    Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–52.CrossRefPubMedGoogle Scholar
  64. 64.
    Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017;177(3):404–13.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Stewart AK, Siegel D, Ludwig H, Facon T, Goldschmidt H, Jakubowiak AJ, San Miguel JF, Obreja M, Blaedel J, Dimopoulos MA. Overall survival (OS) of patients with relapsed/refractory multiple myeloma (RRMM) treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd): final analysis from the randomized phase 3 aspire trial. Blood. 2017;130(Suppl 1):743.Google Scholar
  66. 66.
    Meletios A, Dimopoulos MR, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Repasos E, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E. Cardiac and renal complications of carfilzomib therapy in patients with multiple myeloma. Blood. 2016;128(22):4491.Google Scholar
  67. 67.
    Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral Ixazomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34.CrossRefPubMedGoogle Scholar
  68. 68.
    Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–60.CrossRefPubMedGoogle Scholar
  69. 69.
    Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31.CrossRefPubMedGoogle Scholar
  70. 70.
    Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66.CrossRefPubMedGoogle Scholar
  71. 71.
    Lentzsch S, Weisel KC, Mateos M-V, Hungria V, Munder M, Nooka AK, et al. Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR). J Clin Oncol. 2017;35(15_suppl):8036.Google Scholar
  72. 72.
    Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.CrossRefPubMedGoogle Scholar
  73. 73.
    Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896–905.CrossRefPubMedGoogle Scholar
  74. 74.
    Deleu S, Menu E, Valckenborgh EV, Van Camp B, Fraczek J, Vande Broek I, et al. Histone deacetylase inhibitors in multiple myeloma. Hematol Rev. 2009;1(1):e9.PubMedCentralGoogle Scholar
  75. 75.
    San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–206.CrossRefPubMedGoogle Scholar
  76. 76.
    San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016;3(11):e506–15.CrossRefPubMedGoogle Scholar
  77. 77.
    Farr AM, Stott-Miller M, Varker H, Spencer D, Shah M, Chen C. Treatment sequencing patterns associated with elderly patients with relapsed/refractory multiple myeloma (MM) in the US community setting. Blood. 2015;126(23):5392.Google Scholar
  78. 78.
    Botta C, Ciliberto D, Rossi M, Staropoli N, Cuce M, Galeano T, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Adv. 2017;1(7):455–66.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol. 2017;35(12):1312–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Rosko A, Giralt S, Mateos MV, Dispenzieri A. Myeloma in elderly patients: when less is more and more is more. Am Soc Clin Oncol Educ Book. 2017;37:575–85.CrossRefPubMedGoogle Scholar
  82. 82.
    Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017;129(17):2359–67.CrossRefPubMedGoogle Scholar
  83. 83.
    Larocca A, Palumbo A. How I treat fragile myeloma patients. Blood. 2015;126(19):2179–85.CrossRefPubMedGoogle Scholar
  84. 84.
    Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519–29.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.McMaster UniversityHamiltonCanada
  2. 2.Washington University School of MedicineSt LouisUSA

Personalised recommendations